Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIES-3: Ambrisentan in Pulmonary Hypertension
NCT00380068Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2006
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of ambrisentan in pulmonary hypertension (PH), sponsored by Gilead Sciences. Primary endpoint: 6 Minute Walk Distance at 24 weeks. Started Aug 2006; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT00380068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00380068.